A unique collection of 60 potassium channel blockers and agonists for high throughput and high content screening; Targeting different subtypes of potassium channels, such as Kir1.1, Kir3.x, Kir6.x and Kv7.1, etc. Bioactivity and safety confirmed by pre-clinical research and clinical trials, some of which are FDA approved; Detailed compound information with structure, target, activity, IC50 value, and biological activity description; Structurally diverse, medicinally active, and cell permeable; NMR and HPLC validated to ensure high purity and quality;
